Inactive Instrument

Highlights Oncobiologics Inc Nasdaq

Equities

US68235M2044

End-of-day quote Nasdaq Other stock markets
- ^USD	-

May. 28	Outlook Therapeutics Granted EU Marketing Authorization for Lytenava to Treat Wet AMD	MT
May. 28	Outlook Therapeutics, Inc. Receives European Commission Marketing Authorization for LYTENAVA? (bvacizumab grapa) for the Treatment of Wet AMD	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Outlook Therapeutics Granted EU Marketing Authorization for Lytenava to Treat Wet AMD	May. 28	MT
Outlook Therapeutics, Inc. Receives European Commission Marketing Authorization for LYTENAVA? (bvacizumab grapa) for the Treatment of Wet AMD	May. 28	CI
CoStar Group has room for expansion	May. 21
Outlook Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2024	May. 15	CI
Outlook Therapeutics Submits Marketing Application for Wet Age-related Macular Degeneration Therapy in UK	May. 13	MT
Outlook Therapeutics, Inc. Announces UK Submission of Marketing Authorization Application for ONS-5010 as a Treatment for Wet AMD	May. 13	CI
North American Morning Briefing : Stocks Set for -2-	Mar. 28	DJ
Outlook Therapeutics Reports Secondary Share Offering	Mar. 25	MT
Sector Update: Health Care Stocks Ease Late Afternoon	Mar. 22	MT
Sector Update: Health Care Stocks Ease Friday Afternoon	Mar. 22	MT
Sector Update: Health Care Stocks Steady Pre-Bell Friday	Mar. 22	MT
Outlook Therapeutics Gets EMA Panel Positive Opinion for Wet AMD Treatment -- Shares Rise Pre-Bell	Mar. 22	MT
Outlook Therapeutics Receives European Union Positive CHMP Opinion for ONS-5010 as a Treatment for Wet AMD	Mar. 22	CI
Outlook Therapeutics to Begin Reverse Stock Split for Regaining Nasdaq Compliance	Mar. 12	MT
North American Morning Briefing : S&P 500 Seen -2-	Feb. 16	DJ
Outlook Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended December 31, 2023	Feb. 14	CI
Outlook Therapeutics, Inc. Doses First Subject in Norse Eight	Jan. 31	CI
North American Morning Briefing : Intel Drags Down -2-	Jan. 26	DJ
Outlook Therapeutics Says FDA Clarifies Steps for ONS-5010 Study, Enters Securities Purchase Deals	Jan. 23	MT
Outlook Therapeutics Shares Rally Premarket on ONS-5010 Advances	Jan. 23	DJ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Oncobiologics Inc Nasdaq

Equities

US68235M2044

Highlights

Filters